Navigation Links
Genetic predictor of breast cancer response to chemotherapy
Date:5/11/2012

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy.

The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most benefit to patients whose cancer is driven by HER2 and antiestrogens benefit patients whose breast cancer is hormonally driven. Gene signatures are increasingly available for different cancer types and can be used to predict patient prognosis.

Researchers from McMaster University, in association with the Juravinski Hospital and Cancer Center, analyzed the expression of the enzyme TOP2A (DNA topoisomerase) and β-tubulin, which are the targets of commonly used chemotherapy drugs (anthracycline and taxane) in hundreds of breast tumors. Combining the results from the tumor samples analyses allowed the researchers to build gene expression 'signatures' that measure the susceptibility of tumor cells to chemotherapy.

Both of the 'signatures' were separately able to predict which patients achieved a complete response (where invasive or metastatic cancer could no longer be detected) and together the two indices together were even more accurate at predicting response to chemotherapy.

Prof John Hassell, who led this study, commented, " Our results clearly demonstrate the practicality of using gene expression to personalize chemotherapy treatment for breast cancer patients. Identifying patients who will not benefit from a specific treatment means that they can be moved to a different treatment plan, and the earlier appropriate treatment is started the more likely it is that the patients will benefit from it."


'/>"/>
Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-020-319-22370
BioMed Central
Source:Eurekalert

Page: 1

Related medicine news :

1. Advanced genetic screening method may speed vaccine development
2. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
3. Some women may be genetically predisposed to smoking-related hot flashes
4. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Research Gets Closer to Genetic Roots of Glaucoma
7. Genetic variants, tobacco exposure and lung cancer risk
8. Study of half siblings provides genetic clues to autism
9. Certain Genetic Regions May Be Tied to Osteoporosis
10. Head, Body Lice Are Genetically Very Similar
11. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... PAPA Healthcare, Inc. announced today, the ... Healthcare helps fill gaps, provide essential insights, and improve productivity.” The story ... leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home Infusion ...
(Date:9/19/2017)... BETHESDA, MD (PRWEB) , ... September 19, 2017 ... ... of Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa ... of USAID’s Innovation to Action Award. , The Innovation to Action Award, ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... of its national Swirl: A Wine Tasting Event series on Thursday, October 26, ...
(Date:9/19/2017)... ... 2017 , ... The American College of Lifestyle Medicine ... formed Corporate Roundtable, a group of individuals and organizations whose collective vision is ... Ranch is a unique collection of lifestyle-based immersion vacation settings and programs on ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... 2017 PM360,s annual Innovations Issue, published ... latest innovations happening across the industry. Established six years ... on providing a comprehensive look at the newest and ... most innovative companies, startups, divisions, products, services, and strategies ... "Everyone in this industry wants to do better—in ...
Breaking Medicine Technology: